Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yogesh Patel

Surgery Henderson, NV Medical Doctor

NPI 1891999140 CMS profile 221800

10001 S Eastern Ave Ste 310, Henderson, NV 89052

Open in the dashboard

General payments

$788,078

1,244 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yogesh Patel of Henderson, NV is reported in the CMS Open Payments database as having received $788,078 across 1,244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $136,346 217
2024 General $138,916 248
2023 General $191,396 263
2022 General $103,167 156
2021 General $88,586 111
2020 General $59,288 110
2019 General $70,379 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yogesh Patel
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Yogesh Patel were reported at $136,346. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Yogesh Patel Surgery median Middle half National median
2019 $70,379 $253 $82–$1,521 $163
2020 $59,288 $131 $40–$706 $114
2021 $88,586 $168 $50–$904 $132
2022 $103,167 $224 $76–$1,218 $149
2023 $191,396 $253 $82–$1,255 $160
2024 $138,916 $279 $90–$1,381 $164
2025 $136,346 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $784,449 1,185 payments
  2. Davol Inc. $2,104 15 payments
  3. Boston Scientific Corporation $302 13 payments
  4. AbbVie, Inc. $286 2 payments
  5. Medtronic, Inc. $261 5 payments
  6. Foundation Medicine, Inc. $148 1 payment
  7. Covidien LP $108 3 payments
  8. W. L. Gore & Associates, Inc. $83 3 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $73 4 payments
  10. TELA Bio, Inc. $55 2 payments
  11. Other $207 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $504,852 247 payments
  2. Travel and Lodging $103,367 590 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,500 64 payments
  4. Consulting Fee $60,900 3 payments
  5. Food and Beverage $29,260 339 payments
  6. Gift $199 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $763,799 1,175 payments
  2. DA VINCI SP $20,650 10 payments
  3. Phasix Mesh Surgery $1,303 8 payments
  4. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $286 2 payments
  5. ProGrip $229 3 payments
  6. Phasix Mesh BD Interventional Surgery $212 2 payments
  7. VARITHENA $155 4 payments
  8. FOUNDATIONONE CDX $148 1 payment
  9. FOUNDATIONONE $148 1 payment
  10. FOUNDATIONFOCUS $148 1 payment
  11. Other $1,144 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

101

Median for General Surgery: 59

Drug cost

$645

Median for General Surgery: $393

Branded share of claims

11.9%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erythromycin Erythromycin Base Brand 12 $328
Ibuprofen Generic 72 $234
Neomycin Sulfate Generic 17 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$111,787

Medicare's payments for the services billed

Medicare patients

313

Average age 74

Services billed

612

157 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 38%
Diabetes 37%
Chronic kidney disease 35%
Atrial fibrillation 30%
Heart failure 27%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record